Current Price Disclosure cycle – 2026 April

Page last updated: 5 March 2026

The 2026 April cycle has a data collection period of 1 April 2025 to 30 September 2025.

Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 11 November 2025.

The reduction day is 1 April 2026.

Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.

Contents

Outcomes of Price Disclosure calculations

The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health, Disability and Ageing. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes reflecting these determinations have been published in the National Health (Weighted average disclosed price – April 2026 reduction day) Determination 2025 on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their December 2025 PBS approved ex‑manufacturer price (AEMP) and the weighted average disclosed price (WADP) was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2025 will also take the reduction on 1 April 2026 under section 99ADHA of the Act.

Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The deadline to lodge a dispute is 12 January 2026.

A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices (WADPs) is presented in the table below.

Legal Instrument Drug

Legal Instrument Form

Legal Instrument MoA

Brands of PI designated brands under 99ADHC (Y/N)

Floor Price

Price reduction applied in 2 previous cycles (Y/N)

Average Unadjusted Price Reduction (UPR) at least 12.5% over 3 consecutive cycles (Y/N)

December 2025 AEMP

April 2026 AEMP

Percentage difference between December 2025 and April 2026 AEMP (%)

UPR threshold (%)

Calculations based on:
OWAPD = all brand data, or
GWAPD = originator brand data removed

Abiraterone

Tablet containing abiraterone acetate 250 mg

Oral

N

-

-

-

$876.42

$775.46

11.52%

10%

OWAPD

Abiraterone

Tablet containing abiraterone acetate 500 mg

Oral

N

-

-

-

$876.42

$775.46

11.52%

10%

OWAPD

Amiodarone

Tablet containing amiodarone hydrochloride 200 mg

Oral

Y

$4.73

N

Y

$4.73

$4.00

16.07%

10%

GWAPD

Anastrozole

Tablet 1 mg

Oral

Y

$7.26

N

Y

$7.26

$6.15

15.29%

10%

OWAPD

Aripiprazole

Tablet 10 mg

Oral

Y

$28.47

N

Y

$28.47

$23.55

17.28%

10%

GWAPD

Aripiprazole

Tablet 15 mg

Oral

Y

$40.40

N

Y

$40.40

$33.42

17.28%

10%

GWAPD

Aripiprazole

Tablet 20 mg

Oral

Y

$49.18

N

Y

$49.18

$40.68

17.28%

10%

GWAPD

Aripiprazole

Tablet 30 mg

Oral

Y

$59.93

N

Y

$59.93

$49.57

17.29%

10%

GWAPD

Arsenic

Injection concentrate containing arsenic trioxide 10 mg in 10 mL

Injection

Y

$584.55

N

Y

$584.55

$473.37

19.02%

10%

GWAPD

Atovaquone

Oral suspension 750 mg per 5 mL, 210 mL

Oral

N

-

-

-

$873.50

$670.15

23.28%

10%

OWAPD

Atovaquone with proguanil

Tablet containing atovaquone 250 mg with proguanil hydrochloride 100 mg

Oral

N

-

-

-

$46.03

$39.74

13.67%

10%

GWAPD

Azacitidine

Powder for injection 100 mg

Injection

Y

$25.69

Y

Y

$25.69

$14.63

43.05%

30%

OWAPD

Baclofen

Tablet 10 mg

Oral

Y

$9.28

N

Y

$9.28

$8.25

11.10%

10%

GWAPD

Baclofen

Tablet 25 mg

Oral

Y

$20.28

N

Y

$20.28

$18.03

11.09%

10%

GWAPD

Bevacizumab

Solution for I.V. infusion 100 mg in 4 mL

Injection

N

-

-

-

$53.82

$41.71

22.50%

10%

OWAPD

Bevacizumab

Solution for I.V. infusion 400 mg in 16 mL

Injection

N

-

-

-

$215.28

$166.84

22.50%

10%

OWAPD

Bortezomib

Powder for injection 3 mg

Injection

N

-

-

-

$389.92

$286.63

26.49%

10%

OWAPD

Cabazitaxel

Solution concentrate for I.V. infusion 60 mg in 3 mL

Injection

Y

$88.67

N

Y

$88.67

$71.00

19.93%

10%

OWAPD

Cabazitaxel

Solution concentrate for I.V. infusion 60 mg in 6 mL

Injection

Y

$88.67

N

Y

$88.67

$71.00

19.93%

10%

OWAPD

Cinacalcet

Tablet 30 mg (as hydrochloride)

Oral

N

-

-

-

$19.75

$15.66

20.71%

10%

OWAPD

Cinacalcet

Tablet 60 mg (as hydrochloride)

Oral

N

-

-

-

$39.51

$31.33

20.70%

10%

OWAPD

Cinacalcet

Tablet 90 mg (as hydrochloride)

Oral

N

-

-

-

$59.26

$46.99

20.71%

10%

OWAPD

Clindamycin

Capsule 150 mg (as hydrochloride)

Oral

Y

$4.17

N

Y

$4.17

$4.00

11.75%

10%

GWAPD

Dabigatran etexilate

Capsule 110 mg (as mesilate)

Oral

N

-

-

-

$5.53

$4.57

17.36%

10%

OWAPD

Dabigatran etexilate

Capsule 150 mg (as mesilate)

Oral

N

-

-

-

$32.94

$27.21

17.40%

10%

OWAPD

Darunavir

Tablet 600 mg

Oral

N

-

-

-

$662.53

$577.86

12.78%

10%

OWAPD

Darunavir

Tablet 800 mg

Oral

N

-

-

-

$441.68

$385.23

12.78%

10%

OWAPD

Darunavir

Tablet 800 mg (as ethanolate)

Oral

N

-

-

-

$441.68

$385.23

12.78%

10%

OWAPD

Deferasirox

Tablet, dispersible, 250 mg

Oral

Y

$136.45

N

Y

$136.45

$20.58

84.92%

30%

GWAPD

Deferasirox

Tablet, dispersible, 500 mg

Oral

Y

$395.78

N

Y

$395.78

$59.68

84.92%

30%

GWAPD

Dimethyl fumarate

Capsule (modified release) 120 mg

Oral

N

-

-

-

$114.62

$90.57

20.98%

10%

GWAPD

Enoxaparin

Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe

Injection

N

-

-

-

$71.24

$63.67

10.63%

10%

OWAPD

Enoxaparin

Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe

Injection

N

-

-

-

$80.59

$72.02

10.63%

10%

OWAPD

Enoxaparin

Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL pre-filled syringe

Injection

N

-

-

-

$100.74

$90.03

10.63%

10%

OWAPD

Enoxaparin

Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe

Injection

N

-

-

-

$26.12

$23.34

10.64%

10%

OWAPD

Enoxaparin

Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe

Injection

N

-

-

-

$29.19

$26.09

10.62%

10%

OWAPD

Enoxaparin

Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe

Injection

N

-

-

-

$50.53

$45.16

10.63%

10%

OWAPD

Enoxaparin

Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe

Injection

N

-

-

-

$53.72

$48.01

10.63%

10%

OWAPD

Fenofibrate

Tablet 145 mg

Oral

Y

$6.95

N

Y

$6.95

$5.91

14.96%

10%

GWAPD

Fenofibrate

Tablet 48 mg

Oral

Y

$4.64

N

Y

$4.64

$4.00

14.87%

10%

GWAPD

Fosaprepitant

Powder for I.V. infusion 150 mg

Injection

N

-

-

-

$58.22

$47.63

18.19%

10%

GWAPD

Indapamide

Tablet containing indapamide hemihydrate 2.5 mg

Oral

Y

$4.14

N

Y

$4.14

$4.00

12.08%

10%

GWAPD

Lamotrigine

Tablet 100 mg

Oral

Y

$9.13

N

Y

$9.13

$7.84

14.13%

10%

GWAPD

Lamotrigine

Tablet 200 mg

Oral

Y

$15.35

N

Y

$15.35

$13.18

14.14%

10%

GWAPD

Lamotrigine

Tablet 50 mg

Oral

Y

$5.48

N

Y

$5.48

$4.71

14.05%

10%

GWAPD

Leflunomide

Tablet 10 mg

Oral

Y

$11.88

N

Y

$11.88

$10.15

14.56%

10%

GWAPD

Leflunomide

Tablet 20 mg

Oral

Y

$18.09

N

Y

$18.09

$15.45

14.59%

10%

GWAPD

Lenalidomide

Capsule 10 mg

Oral

N

-

-

-

$400.72

$325.55

18.76%

10%

OWAPD

Lenalidomide

Capsule 15 mg

Oral

N

-

-

-

$482.63

$392.09

18.76%

10%

OWAPD

Lenalidomide

Capsule 25 mg

Oral

N

-

-

-

$631.44

$512.99

18.76%

10%

OWAPD

Lenalidomide

Capsule 5 mg

Oral

N

-

-

-

$305.88

$248.50

18.76%

10%

OWAPD

Levodopa with carbidopa and entacapone

Tablet 100 mg-25 mg (as monohydrate)-200 mg

Oral

N

-

-

-

$56.96

$44.14

22.51%

10%

GWAPD

Levodopa with carbidopa and entacapone

Tablet 125 mg-31.25 mg (as monohydrate)-200 mg

Oral

N

-

-

-

$59.12

$45.81

22.51%

10%

GWAPD

Levodopa with carbidopa and entacapone

Tablet 150 mg-37.5 mg (as monohydrate)-200 mg

Oral

N

-

-

-

$62.35

$48.32

22.50%

10%

GWAPD

Levodopa with carbidopa and entacapone

Tablet 200 mg-50 mg (as monohydrate)-200 mg

Oral

N

-

-

-

$67.31

$52.16

22.51%

10%

GWAPD

Levodopa with carbidopa and entacapone

Tablet 50 mg-12.5 mg (as monohydrate)-200 mg

Oral

N

-

-

-

$51.57

$39.96

22.51%

10%

GWAPD

Levodopa with carbidopa and entacapone

Tablet 75 mg-18.75 mg (as monohydrate)-200 mg

Oral

N

-

-

-

$53.94

$41.80

22.51%

10%

GWAPD

Moclobemide

Tablet 150 mg

Oral

Y

$6.14

N

Y

$6.14

$5.21

15.15%

10%

GWAPD

Moclobemide

Tablet 300 mg

Oral

Y

$10.24

N

Y

$10.24

$8.70

15.04%

10%

GWAPD

Modafinil

Tablet 100 mg

Oral

Y

$55.60

N

Y

$55.60

$48.37

13.00%

10%

GWAPD

Moxonidine

Tablet 200 micrograms

Oral

Y

$4.22

N

Y

$4.22

$4.00

16.11%

10%

GWAPD

Moxonidine

Tablet 400 micrograms

Oral

Y

$7.19

N

Y

$7.19

$6.02

16.27%

10%

GWAPD

Mycophenolic acid

Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL

Oral

Y

$244.51

N

Y

$244.51

$186.10

23.89%

10%

GWAPD

Mycophenolic acid

Tablet (enteric coated) containing mycophenolate sodium equivalent to 360 mg mycophenolic acid

Oral

Y

$171.56

N

Y

$171.56

$130.57

23.89%

10%

GWAPD

Olmesartan with hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg

Oral

Y

$5.49

N

Y

$5.49

$4.72

14.03%

10%

GWAPD

Olmesartan with hydrochlorothiazide

Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg

Oral

Y

$6.20

N

Y

$6.20

$5.33

14.03%

10%

GWAPD

Paclitaxel, nanoparticle albumin-bound

Powder for I.V. injection containing 100 mg paclitaxel

Injection

N

-

-

-

$287.13

$217.82

24.14%

10%

OWAPD

Pegfilgrastim

Injection 6 mg in 0.6 mL single use pre-filled syringe

Injection

Y

$91.63

N

Y

$91.63

$77.52

15.40%

10%

OWAPD

Pomalidomide

Capsule 1 mg

Oral

N

-

-

-

$430.49

$264.06

38.66%

10%

GWAPD

Pomalidomide

Capsule 2 mg

Oral

N

-

-

-

$767.38

$470.72

38.66%

10%

GWAPD

Pomalidomide

Capsule 3 mg

Oral

N

-

-

-

$1,151.07

$706.08

38.66%

10%

GWAPD

Pomalidomide

Capsule 4 mg

Oral

N

-

-

-

$1,534.76

$941.43

38.66%

10%

GWAPD

Pregabalin

Capsule 150 mg

Oral

Y

$7.19

N

Y

$7.19

$5.94

17.39%

10%

GWAPD

Pregabalin

Capsule 300 mg

Oral

Y

$10.72

N

Y

$10.72

$8.85

17.44%

10%

GWAPD

Pregabalin

Capsule 75 mg

Oral

Y

$4.68

N

Y

$4.68

$4.00

17.52%

10%

GWAPD

Rivaroxaban

Tablet 10 mg

Oral

N

-

-

-

$15.33

$11.39

25.70%

10%

OWAPD

Rivaroxaban

Tablet 15 mg

Oral

N

-

-

-

$26.99

$20.05

25.71%

10%

OWAPD

Rivaroxaban

Tablet 2.5 mg

Oral

N

-

-

-

$27.07

$20.11

25.71%

10%

OWAPD

Rivaroxaban

Tablet 20 mg

Oral

N

-

-

-

$26.66

$19.81

25.69%

10%

OWAPD

Sevelamer

Tablet containing sevelamer carbonate 800 mg

Oral

Y

$158.81

N

Y

$158.81

$138.74

12.64%

10%

OWAPD

Sitagliptin

Tablet 100 mg

Oral

N

-

-

-

$19.33

$16.48

14.74%

10%

GWAPD

Sitagliptin

Tablet 25 mg

Oral

N

-

-

-

$19.33

$16.48

14.74%

10%

GWAPD

Sitagliptin

Tablet 50 mg

Oral

N

-

-

-

$19.33

$16.48

14.74%

10%

GWAPD

Sunitinib

Capsule 12.5 mg

Oral

N

-

-

-

$513.55

$456.65

11.08%

10%

GWAPD

Sunitinib

Capsule 25 mg

Oral

N

-

-

-

$1,033.58

$919.06

11.08%

10%

GWAPD

Sunitinib

Capsule 37.5 mg

Oral

N

-

-

-

$1,549.06

$1,377.42

11.08%

10%

GWAPD

Sunitinib

Capsule 50 mg

Oral

N

-

-

-

$2,092.68

$1,860.81

11.08%

10%

GWAPD

Tacrolimus

Capsule 0.75 mg

Oral

Y

$98.08

N

Y

$98.08

$82.07

16.32%

10%

GWAPD

Tamoxifen

Tablet 20 mg (as citrate)

Oral

Y

$4.97

N

Y

$4.97

$4.40

11.47%

10%

GWAPD

Temozolomide

Capsule 100 mg

Oral

Y

$59.70

N

Y

$59.70

$48.19

19.28%

10%

GWAPD

Temozolomide

Capsule 140 mg

Oral

Y

$82.33

N

Y

$82.33

$66.46

19.28%

10%

GWAPD

Temozolomide

Capsule 20 mg

Oral

Y

$13.93

N

Y

$13.93

$11.24

19.31%

10%

GWAPD

Temozolomide

Capsule 250 mg

Oral

Y

$141.84

N

Y

$141.84

$114.49

19.28%

10%

GWAPD

Tenofovir

Tablet containing tenofovir disoproxil fumarate 300 mg

Oral

Y

$77.46

N

Y

$77.46

$56.54

27.01%

10%

GWAPD

Tenofovir

Tablet containing tenofovir disoproxil maleate 300 mg

Oral

Y

$53.38

N

Y

$53.38

$38.96

27.01%

10%

GWAPD

Tenofovir

Tablet containing tenofovir disoproxil phosphate 291 mg

Oral

Y

$53.38

N

Y

$53.38

$38.96

27.01%

10%

GWAPD

Teriflunomide

Tablet 14 mg

Oral

Y

$96.50

N

Y

$96.50

$80.13

16.96%

10%

OWAPD

Topiramate

Tablet 100 mg

Oral

Y

$9.72

N

Y

$9.72

$8.27

14.92%

10%

OWAPD

Topiramate

Tablet 200 mg

Oral

Y

$16.34

N

Y

$16.34

$13.91

14.87%

10%

OWAPD

Topiramate

Tablet 50 mg

Oral

Y

$6.18

N

Y

$6.18

$5.26

14.89%

10%

OWAPD

Trastuzumab

Powder for I.V. infusion 150 mg

Injection

Y

$123.75

N

Y

$123.75

$105.18

15.01%

10%

OWAPD

Trastuzumab

Powder for I.V. infusion 440 mg with diluent

Injection

Y

$320.29

N

Y

$320.29

$272.21

15.01%

10%

OWAPD

Vancomycin

Capsule 125 mg (125,000 I.U.) (as hydrochloride)

Oral

N

-

-

-

$44.16

$39.19

11.25%

10%

GWAPD

Vancomycin

Capsule 250 mg (250,000 I.U.) (as hydrochloride)

Oral

N

-

-

-

$88.30

$78.36

11.26%

10%

GWAPD

Voriconazole

Tablet 200 mg

Oral

Y

$168.54

N

Y

$168.54

$128.24

23.91%

10%

OWAPD

Voriconazole

Tablet 50 mg

Oral

Y

$42.13

N

Y

$42.13

$32.06

23.90%

10%

OWAPD

Flow-on price disclosure reductions

A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction in accordance with the National Health Act 1953 on 1 April 2026 is available in the Pricing-Combination-Flow-on-Price-Reductions-FED-1-APR-2026 (Excel 12KB). Sponsors were able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.

Indicative prices of brands scheduled for a price disclosure reduction

The indicative prices for brands scheduled for price disclosure reductions in this cycle will be published to assist responsible persons and other stakeholders.

Indicative prices are not published for any medicines that are:

  • not taking a price disclosure reduction in this cycle;
  • new brands after the date of publication;
  • brands with other price changes on the reduction day.

Indicative prices reports for non-EFC items can be downloaded below:

Indicative prices reports for EFC items can be downloaded below:

Confirmed prices of brands scheduled for a price disclosure reduction

The Confirmed Prices Report outlines the approved ex‑manufacturer prices (AEMPs) for brands scheduled to take a price disclosure reduction.

The confirmed prices report will be published in March 2026.

Brand price reductions and savings to patients

The Brand Price Reductions and Savings to Patients Report outlines the price disclosure reductions per brand and potential savings to non-concessional patients from 1 April 2026. This information is made available to assist patients understand how much they may save on their PBS medicines.

The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.

The brand price reductions report will be published in March 2026.